Search

Your search keyword '"Caldano, M."' showing total 2 results
Start Over Author "Caldano, M." Publisher elsevier/north-holland
2 results on '"Caldano, M."'

1. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.

Author

Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, Di Sapio A, Capobianco M, Sala A, Malucchi S, Kappos L, Lindberg RL, and Bertolotto A

Subjects
Case-Control Studies, Enzyme-Linked Immunosorbent Assay methods, Female, Follow-Up Studies, GTP-Binding Proteins genetics, GTP-Binding Proteins metabolism, Gene Expression drug effects, Humans, Immunoprecipitation, In Vitro Techniques, Male, Multiple Sclerosis therapy, Myxovirus Resistance Proteins, Neutralization Tests, Receptors, Interferon metabolism, Retrospective Studies, Antibodies therapeutic use, Interferon-beta immunology, Interferon-beta therapeutic use, Multiple Sclerosis immunology
Abstract

Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. Objective of this study was to correlate these measures. Among the 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the IFNbeta activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was inhibited in 9/11 (82%) of these patients. A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo.

Published
2007
Full Text
View/download PDF

2. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

Author

Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, and Bertolotto A

Subjects
Adult, Area Under Curve, Demography, Disability Evaluation, Dose-Response Relationship, Drug, Female, GTP-Binding Proteins drug effects, GTP-Binding Proteins genetics, Humans, Immunologic Factors therapeutic use, Interferon beta-1a, Interferon beta-1b, Interferon-beta immunology, Interferon-beta therapeutic use, Male, Middle Aged, Multiple Sclerosis drug therapy, Myxovirus Resistance Proteins, RNA, Messenger drug effects, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction methods, Time Factors, GTP-Binding Proteins metabolism, Immunologic Factors administration & dosage, Interferon-beta administration & dosage, Multiple Sclerosis metabolism
Abstract

This study is the first to evaluate biological response to first injections of interferon-beta (IFNbeta) in patients with multiple sclerosis. MxA mRNA was measured in 96 patients receiving IFNbeta-1a (Avonex, n=32), IFNbeta-1b (Betaferon, n=19), IFNbeta-1a (Rebif) 22 microg (n=30), or IFNbeta-1a 44 microg (n=15). Patients were analysed before, 3 and 24 h after the first injection, and 12 h after the second administration. Results showed that up-regulation was evident within 3 h of IFNbeta injection, peaked 12 h after injection, and progressively declined 24 h after administration. The cumulative responses were similar after a single administration, regardless of product/dose. Moreover, data indicate that the abolition of the biological activity detected during IFNbeta therapy is due to underlying phenomena (e.g., neutralizing antibodies), because all patients were constitutively responders to IFNbeta at treatment initiation.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results